CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Corvus Pharmaceuticals, Inc. - CRVS CFD

    1.5047
    0%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.0306
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026151 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026151%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003929 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003929%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Corvus Pharmaceuticals Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 1.5047
    Open* 1.4947
    1-Year Change* 99.29%
    Day's Range* 1.4847 - 1.5247
    52 wk Range 0.61-4.19
    Average Volume (10 days) 682.61K
    Average Volume (3 months) 12.34M
    Market Cap 80.30M
    P/E Ratio -100.00K
    Shares Outstanding 48.97M
    Revenue N/A
    EPS -0.84
    Dividend (Yield %) N/A
    Beta 0.99
    Next Earnings Date Nov 1, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Sep 22, 2023 1.5047 0.0100 0.67% 1.4947 1.5247 1.4847
    Sep 21, 2023 1.5047 0.0000 0.00% 1.5047 1.5747 1.4947
    Sep 20, 2023 1.5147 -0.0100 -0.66% 1.5247 1.5947 1.5047
    Sep 19, 2023 1.5547 -0.0100 -0.64% 1.5647 1.5847 1.5247
    Sep 18, 2023 1.5547 0.0000 0.00% 1.5547 1.5747 1.5147
    Sep 15, 2023 1.5747 0.0100 0.64% 1.5647 1.5847 1.5447
    Sep 14, 2023 1.5747 -0.0500 -3.08% 1.6247 1.6447 1.5447
    Sep 13, 2023 1.6147 -0.0900 -5.28% 1.7047 1.7647 1.5947
    Sep 12, 2023 1.7047 -0.0900 -5.01% 1.7947 1.8147 1.6947
    Sep 11, 2023 1.8247 0.0700 3.99% 1.7547 1.9047 1.7047
    Sep 8, 2023 1.6813 0.0800 5.00% 1.6013 1.7213 1.6013
    Sep 7, 2023 1.5613 -0.5100 -24.62% 2.0713 2.1713 1.4713
    Sep 6, 2023 2.0413 -0.0100 -0.49% 2.0513 2.1313 1.9913
    Sep 5, 2023 2.0913 0.0400 1.95% 2.0513 2.1213 2.0313
    Sep 1, 2023 2.0913 0.0300 1.46% 2.0613 2.1413 2.0113
    Aug 31, 2023 2.0713 -0.2400 -10.38% 2.3113 2.3113 2.0613
    Aug 30, 2023 2.2513 0.2800 14.20% 1.9713 2.2713 1.9713
    Aug 29, 2023 2.0013 0.0400 2.04% 1.9613 2.0413 1.9613
    Aug 28, 2023 1.9913 -0.0200 -0.99% 2.0113 2.0513 1.9713
    Aug 25, 2023 2.0213 -0.0100 -0.49% 2.0313 2.0813 1.9813

    Corvus Pharmaceuticals, Inc. Events

    Time (UTC) Country Event
    Wednesday, November 1, 2023

    Time (UTC)

    10:59

    Country

    US

    Event

    Q3 2023 Corvus Pharmaceuticals Inc Earnings Release
    Q3 2023 Corvus Pharmaceuticals Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 0 0 0 0 0
    Total Operating Expense 32.565 38.63 6.301 48.854 49.222
    Selling/General/Admin. Expenses, Total 8.097 9.515 11.93 10.879 10.636
    Research & Development 24.468 29.115 31.83 37.975 38.586
    Operating Income -32.565 -38.63 -6.301 -48.854 -49.222
    Interest Income (Expense), Net Non-Operating -9.351 -4.846 0.306 2.182 2.283
    Net Income Before Taxes -41.307 -43.241 -5.995 -46.672 -46.939
    Net Income After Taxes -41.307 -43.241 -5.995 -46.672 -46.939
    Net Income Before Extra. Items -41.307 -43.241 -5.995 -46.672 -46.939
    Net Income -41.307 -43.241 -5.995 -46.672 -46.939
    Income Available to Common Excl. Extra. Items -41.307 -43.241 -5.995 -46.672 -46.939
    Income Available to Common Incl. Extra. Items -41.307 -43.241 -5.995 -46.672 -46.939
    Diluted Net Income -41.307 -43.241 -5.995 -46.672 -46.939
    Diluted Weighted Average Shares 46.5535 41.8541 29.4789 29.3498 27.51
    Diluted EPS Excluding Extraordinary Items -0.8873 -1.03314 -0.20337 -1.5902 -1.70625
    Dividends per Share - Common Stock Primary Issue
    Diluted Normalized EPS -0.88777 -1.03314 -1.47407 -1.5902 -1.70625
    Unusual Expense (Income) 0 0 -37.459
    Other, Net 0.587 0.235
    Gain (Loss) on Sale of Assets 0.022
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0 0 0 0 0
    Total Operating Expense 5.622 6.574 5.666 12.473 7.013
    Selling/General/Admin. Expenses, Total 1.654 1.98 1.586 2.108 2.09
    Research & Development 3.968 4.594 4.08 10.365 4.923
    Operating Income -5.622 -6.574 -5.666 -12.473 -7.013
    Interest Income (Expense), Net Non-Operating -0.881 -1.355 -4.32 -2.505 -1.496
    Net Income Before Taxes -6.503 -7.873 -9.816 -14.831 -8.363
    Net Income After Taxes -6.503 -7.873 -9.816 -14.831 -8.363
    Net Income Before Extra. Items -6.503 -7.873 -9.816 -14.831 -8.363
    Net Income -6.503 -7.873 -9.816 -14.831 -8.363
    Income Available to Common Excl. Extra. Items -6.503 -7.873 -9.816 -14.831 -8.363
    Income Available to Common Incl. Extra. Items -6.503 -7.873 -9.816 -14.831 -8.363
    Diluted Net Income -6.503 -7.873 -9.816 -14.831 -8.363
    Diluted Weighted Average Shares 47.4974 46.5562 46.5535 46.5535 46.5535
    Diluted EPS Excluding Extraordinary Items -0.13691 -0.16911 -0.21085 -0.31858 -0.17964
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.13691 -0.16911 -0.21133 -0.31858 -0.17964
    Other, Net 0 0.056 0.148 0.147 0.146
    Unusual Expense (Income) 0
    Gain (Loss) on Sale of Assets 0.022
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 43.664 71.312 45.336 79.344 115.589
    Cash and Short Term Investments 42.303 69.451 44.259 77.982 114.597
    Cash & Equivalents 13.159 63.458 16.455 5.154 39.196
    Short Term Investments 29.144 5.993 27.804 72.828 75.401
    Total Receivables, Net 0.633 0.539 0.086 0.329 0.337
    Prepaid Expenses 0.626 1.194 0.585 0.547 0.39
    Other Current Assets, Total 0.102 0.128 0.406 0.486 0.265
    Total Assets 68.24 109.455 85.529 83.646 118.232
    Property/Plant/Equipment, Total - Net 2.57 3.641 2.554 3.789 2.18
    Property/Plant/Equipment, Total - Gross 7.116 7.893 6.346 6.949 4.597
    Accumulated Depreciation, Total -4.546 -4.252 -3.792 -3.16 -2.417
    Other Long Term Assets, Total 0.129 0.236 0.414 0.513 0.463
    Total Current Liabilities 10.752 9.692 12.149 10.225 7.027
    Accounts Payable 1.976 1.565 3.467 2.448 1.998
    Accrued Expenses 8.776 8.127 8.682 7.777 4.869
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 0.16
    Total Liabilities 12.125 12.293 13.381 12.535 7.896
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 1.373 2.601 1.232 2.31 0.869
    Total Equity 56.115 97.162 72.148 71.111 110.336
    Redeemable Preferred Stock 0 0
    Common Stock 0.005 0.005 0.003 0.003 0.003
    Additional Paid-In Capital 364.361 361.669 295.281 288.224 280.84
    Retained Earnings (Accumulated Deficit) -307.688 -266.381 -223.14 -217.145 -170.473
    Other Equity, Total -0.563 1.869 0.004 0.029 -0.034
    Total Liabilities & Shareholders’ Equity 68.24 109.455 85.529 83.646 118.232
    Total Common Shares Outstanding 46.5535 46.5535 28.3726 27.9532 29.3239
    Long Term Investments 21.877 34.266 37.225
    Accounts Receivable - Trade, Net 0.588 0.507
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Total Current Assets 35.551 43.664 51.272 58.885 64.367
    Cash and Short Term Investments 34.467 42.303 49.617 56.723 62.944
    Cash & Equivalents 9.654 13.159 24.588 28.477 31.46
    Short Term Investments 24.813 29.144 25.029 28.246 31.484
    Total Receivables, Net 0.467 0.633 0.534 0.429 0.445
    Prepaid Expenses 0.486 0.626 0.724 1.338 0.848
    Other Current Assets, Total 0.131 0.102 0.397 0.395 0.13
    Total Assets 58.197 68.24 80.348 92.541 101.29
    Property/Plant/Equipment, Total - Net 2.283 2.57 2.914 3.239 3.316
    Property/Plant/Equipment, Total - Gross 6.886 7.116 7.44 7.67 7.655
    Accumulated Depreciation, Total -4.603 -4.546 -4.526 -4.431 -4.339
    Long Term Investments 20.234 21.877 25.914 30.181 33.371
    Other Long Term Assets, Total 0.129 0.129 0.248 0.236 0.236
    Total Current Liabilities 8.29 10.752 13.978 10.156 9.265
    Accounts Payable 1.407 1.976 4.227 2.65 2.189
    Accrued Expenses 6.883 8.776 9.751 7.506 7.076
    Notes Payable/Short Term Debt 0 0 0 0 0
    Total Liabilities 9.33 12.125 15.667 12.155 11.568
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 1.04 1.373 1.689 1.999 2.303
    Total Equity 48.867 56.115 64.681 80.386 89.722
    Common Stock 0.005 0.005 0.005 0.005 0.005
    Additional Paid-In Capital 364.857 364.361 363.741 363.083 362.408
    Retained Earnings (Accumulated Deficit) -315.561 -307.688 -297.872 -283.041 -274.678
    Other Equity, Total -0.434 -0.563 -1.193 0.339 1.987
    Total Liabilities & Shareholders’ Equity 58.197 68.24 80.348 92.541 101.29
    Total Common Shares Outstanding 46.5685 46.5535 46.5535 46.5535 46.5535
    Accounts Receivable - Trade, Net 0.429 0.588 0.503 0.373 0.373
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -41.307 -43.241 -5.995 -46.672 -46.939
    Cash From Operating Activities -27.023 -36.715 -34.778 -37.321 -40.988
    Cash From Operating Activities 0.367 0.46 0.632 0.743 0.847
    Non-Cash Items 12.505 9.302 -31.324 6.704 6.527
    Changes in Working Capital 1.412 -3.236 1.909 1.904 -1.423
    Cash From Investing Activities -23.276 21.56 44.769 3.255 -30.192
    Capital Expenditures -0.269 -0.005 -0.076 -0.025 -0.355
    Other Investing Cash Flow Items, Total -23.007 21.565 44.845 3.28 -29.837
    Cash From Financing Activities 0 62.158 1.31 0.024 65.27
    Financing Cash Flow Items
    Issuance (Retirement) of Stock, Net 0 62.158 1.31 0.024 65.27
    Net Change in Cash -50.299 47.003 11.301 -34.042 -5.91
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -7.873 -41.307 -31.491 -16.66 -8.297
    Cash From Operating Activities -8.111 -27.023 -19.476 -12.547 -6.424
    Cash From Operating Activities 0.057 0.367 0.273 0.179 0.087
    Non-Cash Items 1.959 12.505 7.451 4.146 1.835
    Changes in Working Capital -2.254 1.412 4.291 -0.212 -0.049
    Cash From Investing Activities 4.602 -23.276 -19.394 -22.434 -25.574
    Other Investing Cash Flow Items, Total 4.636 -23.007 -19.125 -22.43 -25.574
    Cash From Financing Activities 0.004 0 0 0
    Issuance (Retirement) of Stock, Net 0.004 0 0 0
    Net Change in Cash -3.505 -50.299 -38.87 -34.981 -31.998
    Capital Expenditures -0.034 -0.269 -0.269 -0.004

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Corvus Pharmaceuticals, Inc. Company profile

    About Corvus Pharmaceuticals Inc

    Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which is engaged in the development and commercialization of precisely targeted oncology therapies. The Company develops drugs and antibodies that target the critical cellular elements of the immune system. The Company's lead product candidate is CPI-006, a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its next product candidate, CPI-818, is a selective, covalent inhibitor of ITK. CPI-818 is designed to inhibit the proliferation of certain malignant T-cells. Its third product candidate, Ciforadenant is an oral, small molecule antagonist of the A2A receptor for adenosine. Its product candidate pipeline includes CPI-006, B-Cell Activating anti-CD73 antibody; CPI-818, ITK Inhibitor, Ciforadenant Adenosine A2A Receptor Antagonist; CPI-182, Anti-CXCR2 Antibody designed to block inflammation and Myeloid Suppression; and CPI-935, Adenosine A2B Receptor Antagonist.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Corvus Pharmaceuticals Inc revenues was not reported. Net loss increased from $6M to $43.2M. Higher net loss reflects Gain on deconsolidation of Angel Pharmac decrease from $37.5M (income) to $0K, Loss from equity method investment increase from $234K to $4.8M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.20 to -$1.03.

    Industry: Biotechnology & Medical Research (NEC)

    863 Mitten Rd Ste 102
    BURLINGAME
    CALIFORNIA 94010-1311
    US

    Income Statement

    • Annual
    • Quarterly

    News

    EUR/USD tests key support

    EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

    14:32, 21 September 2023
    Bank of England building

    BoE leaves rates unchanged, GBP drops further as investors look for more clarity

    The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

    11:45, 21 September 2023
    British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

    GBP softer after CPI surprise, JPY focused on any further hints from Ueda

    GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

    12:42, 20 September 2023

    How to Trade The Break & Retest

    In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

    11:59, 20 September 2023

    Cable coils near lows ahead of Fed and BoE rate decisions

    It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

    14:16, 19 September 2023

    FTSE 100 Technical Outlook - 18 September 2023

    In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.

    06:55, 19 September 2023
    View of the City of London’s illuminated financial district skyline at dusk

    Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally

    The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.

    13:46, 15 September 2023

    People also watch

    XRP/USD

    0.52 Price
    +0.280% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01192

    BTC/USD

    26,629.30 Price
    +0.010% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 85.00

    US100

    14,710.90 Price
    +0.190% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0039%
    Overnight fee time 21:00 (UTC)
    Spread 7.0

    ETH/USD

    1,596.83 Price
    +0.150% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 5.40

    Still looking for a broker you can trust?

    Join the 555.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading